Molecular Targets for Cancer Therapy in the PI3K/AKT/mTOR Pathway
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F14%3A10146044" target="_blank" >RIV/00216208:11140/14:10146044 - isvavai.cz</a>
Alternative codes found
RIV/00669806:_____/14:10146044
Result on the web
<a href="http://dx.doi.org/10.1016/j.pharmthera.2013.12.004" target="_blank" >http://dx.doi.org/10.1016/j.pharmthera.2013.12.004</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.pharmthera.2013.12.004" target="_blank" >10.1016/j.pharmthera.2013.12.004</a>
Alternative languages
Result language
angličtina
Original language name
Molecular Targets for Cancer Therapy in the PI3K/AKT/mTOR Pathway
Original language description
Aberrations in various cellular signaling pathways are instrumental in regulating cellular metabolism, tumor development, growth, proliferation, metastasis and cytoskeletal reorganization. The fundamental cellular signaling cascade involved in these processes, the phosphatidylinositol 3-kinase/protein kinase-B/mammalian target of rapamycin (PI3K/AKT/mTOR), closely related to the mitogen-activated protein kinase (MAPK) pathway, is a crucial and intensively explored intracellular signaling pathway in tumorigenesis. Various activating mutations in oncogenes together with the inactivation of tumor suppressor genes are found in diverse malignancies across almost all members of the pathway. Substantial progress in uncovering PI3K/AKT/mTOR alterations and their roles in tumorigenesis has enabled the development of novel targeted molecules with potential for developing efficacious anticancer treatment. Two approved anticancer drugs, everolimus and temsirolimus, exemplify targeted inhibition of
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
EB - Genetics and molecular biology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/ED2.1.00%2F03.0076" target="_blank" >ED2.1.00/03.0076: Biomedical Centre of the Faculty of Medicine in Pilsen</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Pharmacology and Therapeutics
ISSN
0163-7258
e-ISSN
—
Volume of the periodical
142
Issue of the periodical within the volume
2
Country of publishing house
GB - UNITED KINGDOM
Number of pages
12
Pages from-to
164-175
UT code for WoS article
000334135000003
EID of the result in the Scopus database
—